uspto.gov
Skip over navigation

August 16, 2011

CONTACT: (Media Only)
Peter Pappas or Jennifer Rankin Byrne
(571) 272-8400 or
peter.pappas@uspto.gov,
jennifer.rankin_byrne@uspto.gov

Press Release, 11-47

United States Patent and Trademark Office Issues Patent Number 8,000,000

Patent Awarded to Second Sight Medical Products for a “Visual Prosthesis Apparatus” that Enhances Visual Perception for the Sight Impaired

WASHINGTON – The Department of Commerce’s United States Patent and Trademark Office (USPTO) today issued patent number 8,000,000 to Second Sight Medical Products, Inc., for a visual prosthesis apparatus that enhances visual perception for people who have gone blind due to outer retinal degeneration. The invention uses electrical stimulation of the retina to produce the visual perception of patterns of light. The product, the Argus® II, is currently in U.S. clinical trials and has received marketing approval in Europe.

“This kind of innovation is a driver of our nation’s economic growth and job creation,” said Under Secretary of Commerce for Intellectual Property and Director of the USPTO David Kappos. “The USPTO plays a major role in serving America’s innovators by granting the intellectual property rights they need to secure investment capital, build companies and bring their products and services to the global marketplace.”

“Second Sight has 90 issued U.S. patents surrounding technology associated with sight restoration for the blind and treatment of a variety of other medical conditions,” said Robert Greenberg, president and CEO of Second Sight. “This patent protection and significant federal support for innovation have already played key roles in creating nearly 100 U.S. jobs at our company. Once the Argus II has FDA approval in the United States, we expect to create hundreds of more jobs over the next several years, while delivering a breakthrough treatment for a previously untreatable medical condition.”

It took 75 years to get to patent 1 million in August 1911, yet just under six years to get from patent number 7,000,000 to today’s patent number 8,000,000.  More information on these milestones is available online.   

About Patent Number 8,000,000

In a healthy eye, the photoreceptors (rods and cones) on the retina convert light into tiny electrochemical impulses that are sent through the optic nerve and into the brain, where they are decoded into images.  If the photoreceptors no longer function correctly, the first step in this process is disrupted and the visual system cannot transform light into images, causing blindness. 

The system awarded patent number 8,000,000 is designed to bypass the damaged photoreceptors altogether.  A miniature video camera housed in the patient’s glasses sends information to a small computer worn by the patient where it is processed and transformed into instructions transmitted wirelessly to a receiver in an implanted stimulator.  The signals are then sent to an electrode array, attached to the retina, which emits small pulses of electricity.  These electrical pulses are intended to bypass the damaged photoreceptors and stimulate the retina’s remaining cells to transmit the visual information along the optic nerve to the brain. 

The signing and presentation of the 8 millionth patent by Director Kappos will take place at the Smithsonian American Art Museum on September 8, 2011.

About Second Sight Medical Products

Second Sight Medical Products, Inc., located in Sylmar, Calif., is a privately held company founded in 1998 by Alfred Mann, Dr. Sam Williams and Gunnar Bjorg with the goal of creating a retinal prosthesis to provide sight to subjects blinded from outer retinal degenerations, such as retinitis pigmentosa.

For more information about Second Sight Medical Products, please visit www.2-sight.com or call 818-833-5026. Second Sight and Argus are registered trademarks of Second Sight Medical Products, Inc.

To stay current with the USPTO, subscribe to regular email updates at www.uspto.gov/subscribe.

###

United States Patent and Trademark Office
This page is owned by Office of the Chief Communications Officer.
Last Modified: 12/5/2012 3:22:25 PM